Researchers of an open-label clinical trial have reported promising results using tapinarof cream 1% alongside injectable biologics for adult plaque psoriasis treatment. The trial, which aimed to meet the National Psoriasis Foundation’s (NPF) treat-to-target goal of reducing psoriasis to 1% body surface area or less within 3 months, involved 30 patients already on stable biologic therapy for at least 26 weeks. These patients applied tapinarof cream daily for 12 weeks in addition to their ongoing biologic regimen. Assessments at week 16, four weeks after discontinuing tapinarof cream, showed that 52% of patients achieved the NPF goal, with a notable 75% reduction in Psoriasis Area and Severity Index scores at week 12, a reduction that was maintained at week 16.
The study highlighted positive effects for patients with genital psoriasis, where all three patients achieved genital clearance by week 12. Notably, tapinarof cream was well-tolerated and safe when used with injectable biologics, with no severe adverse events reported except a mild case of folliculitis. The study also emphasized the cost benefits, as this combination therapy could extend the usage of biologics instead of frequently switching agents, reducing overall healthcare costs and the burden on patients and healthcare providers.
Reference: Buchanan L. Psoriasis Treatment Center of New Jersey Reports Positive Results for Tapinarof in Psoriasis Trial. Dermatology Times. Published December 13, 2023. Accessed March 13, 2024. https://www.dermatologytimes.com/view/psoriasis-treatment-center-of-new-jersey-reports-positive-results-for-tapinarof-in-psoriasis-trial
